Pacibekitug

Tourmaline Bio’s Phase 2 TRANQUILITY trial of pacibekitug demonstrated significant hs-CRP reductions in patients with elevated hs-CRP and chronic kidney disease. The 50mg quarterly dose achieved >85% hs-CRP reduction, a first for an IL-6 inhibitor. Statistically significant reductions were also observed in cardiovascular risk biomarkers like lipoprotein(a) and fibrinogen. These results support planned Phase 2 AAA study and Phase 3 ASCVD cardiovascular outcomes trial.